Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 7/20 | 0.66 |
| ▸ | PTGDR | Q13258 | 7/20 | 0.66 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.66 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.66 |
| ▸ | PTGFR | P43088 | 1/20 | 0.66 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.66 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.38 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.38 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | FABP4 | P15090 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22276282 | 0.95 | PTGER4 (0.65) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL23879095 | 0.94 | PTGER4 (0.67) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL29403055 | 0.94 | PTGER4 (0.67) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL29406591 | 0.90 | PTGER4 (0.61) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL20542005 | 0.89 | PTGER4 (0.67) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL29403043 | 0.89 | PTGER4 (0.51) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL23879087 | 0.89 | PTGER4 (0.51) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL22276287 | 0.89 | PTGER4 (0.66) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL22276284 | 0.88 | PTGER4 (0.60) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL31070930 | 0.86 | PTGER4 (0.61) | PTGER4PTGDRTBXA2RPTGER1PTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240812-B2 | Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof | Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) | 2025-03-04 | — | — | US | disclosed |
| EP-3889134-B1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | KEYTHERA SUZHOU PHARMACEUTICALS CO LTD (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-111989311-B | Compound for inhibiting PGE2/EP4 signal transduction, preparation method thereof and application thereof in medicines | 凯复(苏州)生物医药有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20220064113-A1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) | 2022-03-03 | — | — | US | disclosed |
| EP-3889134-A1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| EP-3889134-A1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020151566-A1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | 凯复制药有限公司 | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064113-A1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | PTGER4, PTGER1, PTGES | PTGER4 1/4885PTGDR 15/4885TBXA2R 28/4885 |
| US-12240812-B2 | Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof | PTGER4, PTGER1, PTGES | PTGER4 1/4885PTGDR 15/4885TBXA2R 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.